"Recent findings published in the Journal of the American Medical Association (JAMA) underscore US oncologists' concerns regarding potential errors in cancer treatment stemming from artificial intelligence (AI) applications.
The study, featured in JAMA, surveyed 204 oncology experts practicing in the US between November 2022 and July 2023. Results revealed that nearly 90% of respondents advocated for AI developers to be held accountable for any legal ramifications arising from the use of AI in cancer treatment.
When it came to assigning responsibility, opinions varied among oncologists, with 47.1% suggesting doctors bear the brunt while 43.1% believed hospitals should share the accountability burden. Additionally, an overwhelming 81.4% of respondents emphasized the importance of obtaining patient consent for AI-assisted treatments.
Addressing potential conflicts between AI recommendations and physicians' expertise, 36.8% of American physicians recommended granting patients the final decision-making authority.
As the US Food and Drug Administration (FDA) greenlights AI models for oncological use, experts acknowledge AI's potential to revolutionize cancer treatment. Nevertheless, the survey underscores the pressing need for clear guidelines on responsibility and accountability within AI-assisted cancer care.
News ID : 3111